Shots:

• The P-I study will evaluate the PK and safety profile of R-107 vs PBO in patients with PAH. Earlier- Claritas licensed R-107 from Salzman Group and collaborated with it- under which get an exclusive WW right to develop R-107 for the treatment of PAH
• CMAX will initiate a P-Ia study for R-107 (IM) and enroll 32 healthy middle-aged volunteers in 4 ascending dose cohorts. The study is expected to begin enrollment in Q3’21 with 2mos. duration
• The P-Ia data will support the POC P-IIa study for the treatment of PAH patients undergoing cardiac catherization as part of their routine medical care. The study is expected to be initiated in H1’22

  Ref: Globe Newswire | Image: Fresh 92.7